Teva Pharmaceuticals (NYSE:TEVA) has been engulfed with turmoil. Its blockbuster MS franchise is facing a new competitive thereat, and the company is staring down the barrel of its patent expiration. Then in October, we saw the surprise departure of still-new-on-the-job CEO Jeremy Levin.
Teva has not stood still. This past week has seen the company jump into the bidding for NuPathe (UNKNOWN:PATH.DL), topping Endo Health's (NASDAQ:ENDP) offer for the former's FDA-approved migraine patch. More importantly, it filled the vacancy in its CEO suite. Board member Erez Vigodman is set to take over, and has been hailed as an excellent choice, but he has a challenging road ahead.
In this video Motley Fool health-care analyst David Williamson discusses the competing NuPathe deals and what they mean for investors in both stocks, as well as the challenges Teva's new CEO will face and the important questions he must answer.
Our top stock for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.